Business Wire

Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the ...
Business Wire

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

Shield is commercially available for eligible individuals by prescription only through healthcare professionals. This LDT (Laboratory Developed Test) is intended to be complementary to, and not a ...
Seeking Alpha

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, ...
Morningstar

Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...
Seeking Alpha

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...